Journal article icon

Journal article

Permeabilisation of tumour margins in brain macrometastases using a type-1 receptor selective tumour necrosis factor mutein

Abstract:
Background Brain metastasis remains a major clinical challenge. The blood-brain barrier (BBB), which persists in the margins even in late-stage macrometastases, is a major impediment to effective drug delivery, surgery or radiotherapy. The aim of this study was to determine whether a mutein of human tumour necrosis factor (TNF) that is selective for the TNFR1 receptor could increase permeabilisation in the margins of brain metastases, enabling better delineation and more complete treatment. Methods Intracerebral xenograft mouse models of breast cancer (MDA231Br-GFP), melanoma (H1_DL2) and lung cancer (SEBTA) brain metastasis were used to test the efficacy of the TNF mutein (mutTNF) in permeabilising the margins of well-established macrometastases. Changes in tumour permeabilisation were assessed in vivo by gadolinium-enhanced magnetic resonance imaging (MRI) and ex vivo by IgG immunohistochemistry. Results Tumour margin permeabilisation was increased following mutTNF treatment in all three models. The MDA231Br-GFP model showed a significant increase in the extent of both gadolinium enhancement (P<0.01) and IgG extravasation (P<0.05), whilst significant effects were detected by MRI alone in the SEBTA (P<0.01) and H1_DL2 (P<0.05) models. Although a strong trend towards increased IgG extravasation was found in the SEBTA model (P=0.076). Consistent with these findings, the models showed differing degrees of both infiltration and vascular TNFR1 expression at the margins (MDA231Br-GFP > SEBTA > H1_DL2), suggesting a greater sensitivity to mutTNF with increasing marginal invasiveness. Conclusions This work demonstrates the potential of TNFR1 selective mutTNF as an adjuvant strategy to improve tumour margin delineation and enhance therapeutic access in brain metastases.
Publication status:
Accepted
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1093/noajnl/vdag239

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
ORCID:
0000-0003-1791-5912
More by this author
Institution:
University of Oxford
Division:
MSD
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Pharmacology
Role:
Author
ORCID:
0000-0003-1380-6655
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
ORCID:
0000-0003-0167-1685


More from this funder
Funder identifier:
https://ror.org/03x94j517
Grant:
MR/V005995/1
MR/N028031/1


Publisher:
Oxford University Press
Journal:
Neuro-Oncology Advances More from this journal
Acceptance date:
2026-08-31
DOI:
EISSN:
2632-2498


Language:
English
Keywords:
Pubs id:
2455085
Local pid:
pubs:2455085
Deposit date:
2026-09-07
ARK identifier:


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP